These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 35836807)

  • 1. SGLT2 inhibitor dapagliflozin reduces endothelial dysfunction and microvascular damage during cardiac ischemia/reperfusion injury through normalizing the XO-SERCA2-CaMKII-coffilin pathways.
    Ma L; Zou R; Shi W; Zhou N; Chen S; Zhou H; Chen X; Wu Y
    Theranostics; 2022; 12(11):5034-5050. PubMed ID: 35836807
    [No Abstract]   [Full Text] [Related]  

  • 2. Ripk3 regulates cardiac microvascular reperfusion injury: The role of IP3R-dependent calcium overload, XO-mediated oxidative stress and F-action/filopodia-based cellular migration.
    Zhou H; Wang J; Zhu P; Hu S; Ren J
    Cell Signal; 2018 May; 45():12-22. PubMed ID: 29413844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empagliflozin attenuates cardiac microvascular ischemia/reperfusion injury through improving mitochondrial homeostasis.
    Zou R; Shi W; Qiu J; Zhou N; Du N; Zhou H; Chen X; Ma L
    Cardiovasc Diabetol; 2022 Jun; 21(1):106. PubMed ID: 35705980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BI1 alleviates cardiac microvascular ischemia-reperfusion injury via modifying mitochondrial fission and inhibiting XO/ROS/F-actin pathways.
    Zhou H; Wang J; Hu S; Zhu H; Toanc S; Ren J
    J Cell Physiol; 2019 Apr; 234(4):5056-5069. PubMed ID: 30256421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Empagliflozin attenuates cardiac microvascular ischemia/reperfusion through activating the AMPKα1/ULK1/FUNDC1/mitophagy pathway.
    Cai C; Guo Z; Chang X; Li Z; Wu F; He J; Cao T; Wang K; Shi N; Zhou H; Toan S; Muid D; Tan Y
    Redox Biol; 2022 Jun; 52():102288. PubMed ID: 35325804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empagliflozin and Dapagliflozin Reduce ROS Generation and Restore NO Bioavailability in Tumor Necrosis Factor α-Stimulated Human Coronary Arterial Endothelial Cells.
    Uthman L; Homayr A; Juni RP; Spin EL; Kerindongo R; Boomsma M; Hollmann MW; Preckel B; Koolwijk P; van Hinsbergh VWM; Zuurbier CJ; Albrecht M; Weber NC
    Cell Physiol Biochem; 2019; 53(5):865-886. PubMed ID: 31724838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac ischemia-reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity.
    Yoshii A; Nagoshi T; Kashiwagi Y; Kimura H; Tanaka Y; Oi Y; Ito K; Yoshino T; Tanaka TD; Yoshimura M
    Cardiovasc Diabetol; 2019 Jul; 18(1):85. PubMed ID: 31262297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective effect of HINT2 on mitochondrial function via repressing MCU complex activation attenuates cardiac microvascular ischemia-reperfusion injury.
    Li S; Chen J; Liu M; Chen Y; Wu Y; Li Q; Ma T; Gao J; Xia Y; Fan M; Chen A; Lu D; Su E; Xu F; Chen Z; Qian J; Ge J
    Basic Res Cardiol; 2021 Dec; 116(1):65. PubMed ID: 34914018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dapagliflozin: A sodium-glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced atrial fibrillation by regulating atrial electrical and structural remodeling.
    Zhan G; Wang X; Wang X; Li J; Tang Y; Bi H; Yang X; Xia Y
    Eur J Pharmacol; 2024 Sep; 978():176712. PubMed ID: 38906237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adiponectin regulates SR Ca(2+) cycling following ischemia/reperfusion via sphingosine 1-phosphate-CaMKII signaling in mice.
    Yan W; Zhang F; Zhang R; Zhang X; Wang Y; Zhou F; Xia Y; Liu P; Gao C; Wang H; Zhang L; Zhou J; Gao F; Gao E; Koch WJ; Wang H; Cheng H; Qu Y; Tao L
    J Mol Cell Cardiol; 2014 Sep; 74():183-92. PubMed ID: 24852843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium.
    Cappetta D; De Angelis A; Ciuffreda LP; Coppini R; Cozzolino A; Miccichè A; Dell'Aversana C; D'Amario D; Cianflone E; Scavone C; Santini L; Palandri C; Naviglio S; Crea F; Rota M; Altucci L; Rossi F; Capuano A; Urbanek K; Berrino L
    Pharmacol Res; 2020 Jul; 157():104781. PubMed ID: 32360273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The histone deacetylase inhibitor SAHA exerts a protective effect against myocardial ischemia/reperfusion injury by inhibiting sodium-calcium exchanger.
    Shi X; Yin Y; Guo X; Liu M; Ma F; Tian L; Zheng M; Liu G
    Biochem Biophys Res Commun; 2023 Sep; 671():105-115. PubMed ID: 37300940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPKα/TGF-β/Smad signalling in type 2 diabetic rats.
    Tian J; Zhang M; Suo M; Liu D; Wang X; Liu M; Pan J; Jin T; An F
    J Cell Mol Med; 2021 Aug; 25(16):7642-7659. PubMed ID: 34169635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct cardio-protection of Dapagliflozin against obesity-related cardiomyopathy via NHE1/MAPK signaling.
    Lin K; Yang N; Luo W; Qian JF; Zhu WW; Ye SJ; Yuan CX; Xu DY; Liang G; Huang WJ; Shan PR
    Acta Pharmacol Sin; 2022 Oct; 43(10):2624-2635. PubMed ID: 35217813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardioprotection by selective SGLT-2 inhibitors in a non-diabetic mouse model of myocardial ischemia/reperfusion injury: a class or a drug effect?
    Nikolaou PE; Mylonas N; Makridakis M; Makrecka-Kuka M; Iliou A; Zerikiotis S; Efentakis P; Kampoukos S; Kostomitsopoulos N; Vilskersts R; Ikonomidis I; Lambadiari V; Zuurbier CJ; Latosinska A; Vlahou A; Dimitriadis G; Iliodromitis EK; Andreadou I
    Basic Res Cardiol; 2022 May; 117(1):27. PubMed ID: 35581445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dapagliflozin alleviates myocardial ischemia/reperfusion injury by reducing ferroptosis
    Chen W; Zhang Y; Wang Z; Tan M; Lin J; Qian X; Li H; Jiang T
    Front Pharmacol; 2023; 14():1078205. PubMed ID: 36891270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dapagliflozin attenuates hypoxia/reoxygenation-caused cardiac dysfunction and oxidative damage through modulation of AMPK.
    Tsai KL; Hsieh PL; Chou WC; Cheng HC; Huang YT; Chan SH
    Cell Biosci; 2021 Feb; 11(1):44. PubMed ID: 33637129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic Empagliflozin Treatment Reduces Myocardial Infarct Size in Nondiabetic Mice Through STAT-3-Mediated Protection on Microvascular Endothelial Cells and Reduction of Oxidative Stress.
    Nikolaou PE; Efentakis P; Abu Qourah F; Femminò S; Makridakis M; Kanaki Z; Varela A; Tsoumani M; Davos CH; Dimitriou CA; Tasouli A; Dimitriadis G; Kostomitsopoulos N; Zuurbier CJ; Vlahou A; Klinakis A; Brizzi MF; Iliodromitis EK; Andreadou I
    Antioxid Redox Signal; 2021 Mar; 34(7):551-571. PubMed ID: 32295413
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of dapagliflozin on ferroptosis through the gut microbiota metabolite TMAO during myocardial ischemia-reperfusion injury in diabetes mellitus rats.
    Wang L; Wang Y; Xu H; Li W
    Sci Rep; 2024 Jun; 14(1):13851. PubMed ID: 38879701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of the zinc transporter SLC39A13 (ZIP13) is responsible for the activation of CaMKII at reperfusion and leads to myocardial ischemia/reperfusion injury in mouse hearts.
    Wang J; Cheng X; Zhao H; Yang Q; Xu Z
    J Mol Cell Cardiol; 2021 Mar; 152():69-79. PubMed ID: 33307093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.